Strategic implications for the 340B Rebate Model Pilot Program
These entities receive discounts on all eligible covered outpatient drugs. The program has expanded substantially over the years, with the number of covered...
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
For more than 25 years, life science companies, law firms, and regulatory agencies around the globe have turned to CRA’s life sciences consultants when they need clarity and solutions to the industry’s most complex issues. Clients value our deep industry knowledge, rigorous analytic techniques, and decades of hands-on experience spanning thousands of successful engagements.
These entities receive discounts on all eligible covered outpatient drugs. The program has expanded substantially over the years, with the number of covered...
MFN-related uncertainty is reshaping pharmaceutical launch planning by making pricing, sequencing, and forecasting decisions more interconnected and...
CRA is a proud sponsor of the Educational Symposia session titled “The Oncology Combination Therapy Dilemma: Can Today’s HTA Systems Support Tomorrow’s...
CRA is a proud sponsor of the conference. Greg Bell speaks during the session titled “Damages in Pharma & Biotech Litigation: What Courts are Accepting...
CRA is a proud sponsor of the conference dedicated to providing invaluable opportunities for networking and collaboration with the chance to meet, engage with...
CRA is a proud sponsor of the summit. Simon Chisholm is a speaker during the session titled “Understanding Lessons and Takeaways from Market Investigations”...
